Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, patients with active lymphocytic cicatricial alopecia showed significant improvement using a three-stage treatment regimen involving Tofacitinib, Apremilast, and Crisaborole, with 93.5% experiencing marked improvement and only three mild adverse events reported.

In this case report, a 25-year-old female with Mixed Connective Tissue Disease presented unusual symptoms in a specific geographical region, prompting clinicians to approach diagnosis and management with caution due to potential severe complications such as pulmonary hypertension and renal crisis.

This study reports that Abelson Interactor 1 (ABI1) regulates androgen receptor transcription in prostate cancer, identifying it as a potential target for new therapies addressing treatment resistance.

This study reported that 7.80% of systemic lupus erythematosus patients experienced scarring alopecia, with mucocutaneous lesions and certain autoantibodies identified as risk factors, and some organ involvements and immunosuppressants as protective factors.

A patient had both chronic lupus and systemic scleroderma, requiring careful treatment to manage symptoms.

This study reported that postmenopausal patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival over therapy-related side effects when considering cancer treatment decisions.

This review discusses the potential use of cannabidiol (CBD) for managing COVID-19 patients, especially for controlling cytokine storms in those with acute respiratory distress syndrome, but reports no new clinical results.

This report describes common skin CT features of rosacea identified using a reflective confocal microscope, facilitating more objective diagnosis but highlights the need for further clinical exploration.

This study identifies novel genetic variants in the NOTCH3 and HTRA1 genes associated with CADASIL and CARASIL, highlighting their potential in supporting clinical diagnosis and informing treatment strategies.

This case report describes a 21-year-old woman with circumscribed alopecia areata incognita, who experienced a sustained positive response to treatment with oral tofacitinib after conventional treatments frequently failed to provide lasting effects.

This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.

This study found that patients with alopecia areata may have higher rates of autoimmune disorders, particularly thyroid dysfunction, compared to the general population.

This review found that oral JAK inhibitors, used off-label in various inflammatory skin disorders, often resulted in rapid and sustained clinical improvements with acceptable safety over several months, although the evidence is drawn from case-based reports.

This study found that most chronic alopecia areata patients treated with azathioprine, methotrexate, or cyclosporine continued treatment for at least 12 months, often requiring concurrent low-dose prednisolone.

This study found that elevated tissue RBP4 levels correlate with disease severity in alopecia areata and decrease after effective baricitinib treatment, while the rs3758539 polymorphism is linked to disease susceptibility but not to treatment response.

This study found that ACOD1 deficiency in dermal papilla cells promotes mitochondrial dysfunction and contributes to cellular senescence in androgenetic alopecia, suggesting ACOD1 as a potential therapeutic target and 4-octyl itaconate as a promising treatment option for AGA.

This study reviews both traditional and innovative therapies for alopecia areata, focusing on the potential benefits and challenges of newer targeted treatments while introducing GRASS-UK/GRASS-International as networks aimed at assessing the long-term safety and effectiveness of these therapies worldwide.

This research aims to address gaps in understanding alopecia areata by evaluating the real-world effectiveness and safety of baricitinib, identifying predictors of therapeutic response, and exploring the long-term impact on life quality, including sexual health. Results are not reported in the abstract.

In this retrospective study of eight Saudi children with hereditary vitamin D resistant rickets, researchers observed that adjunctive cinacalcet appeared safe and showed initial promise in improving serum PTH levels, though further investigation is needed to confirm its efficacy.

This case report details a 17-year-old male with Alopecic and Aseptic Nodules of the Scalp successfully treated with doxycycline and intralesional corticosteroids, highlighting the importance of thorough evaluation for accurate diagnosis.

The care model improved timely diagnosis and treatment for psoriasis and psoriatic arthritis.

This study found fractional carbon dioxide laser therapy effective in treating alopecia areata, both alone and with topical treatments, suggesting decorin's involvement in improving hair growth.

This case report describes an 18-year-old male whose acne, unresponsive to traditional treatments and only partially improved with oral isotretinoin, was linked to androgen metabolism anomalies indicative of a non-classical form of congenital adrenal hyperplasia.

This source summarizes the new 2024 American Academy of Dermatology guidelines, emphasizing strong recommendations for topical and oral therapies like benzoyl peroxide, doxycycline, and isotretinoin in managing acne vulgaris, while outlining the importance of tailored treatments for diverse patient needs in Canadian practice.

This review by Aceituno et al. found that both baricitinib and ritlecitinib demonstrate strong efficacy for severe alopecia areata, with meaningful hair regrowth by Week 24, but notes limitations like differing trial sizes and potential effect size overestimations.